Trial Profile
A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms NACRE
- 26 Jul 2022 Status changed from active, no longer recruiting to completed.
- 11 Feb 2021 Planned End Date changed from 1 Mar 2030 to 1 Aug 2030.
- 11 Feb 2021 Status changed from recruiting to active, no longer recruiting.